Details of Drug-Metabolizing Enzyme (DME)
Full List of Drug(s) Metabolized by This DME | |||||
---|---|---|---|---|---|
Drugs Approved by FDA | Click to Show/Hide the Full List of Drugs: 66 Drugs | ||||
Darolutamide |
Drug Info | Approved | Prostate cancer | ICD11: 2C82 | [1] |
Dronabinol |
Drug Info | Approved | Anorexia nervosa | ICD11: 6B80 | [2] |
Diclofenac sodium |
Drug Info | Approved | Osteoarthritis | ICD11: FA00 | [3] |
Montelukast sodium |
Drug Info | Approved | Asthma | ICD11: CA23 | [2], [4] |
Ethinyl estradiol |
Drug Info | Approved | Menopausal disorder | ICD11: GA30 | [5] |
Irbesartan |
Drug Info | Approved | Essential hypertension | ICD11: BA00 | [2] |
Pitavastatin |
Drug Info | Approved | Hypertriglyceridaemia | ICD11: 5C80 | [6] |
Valproic acid |
Drug Info | Approved | Epilepsy | ICD11: 8A60 | [7] |
Aprepitant |
Drug Info | Approved | Functional nausea/vomiting | ICD11: DD90 | [8] |
Cyproheptadine |
Drug Info | Approved | Rheumatoid arthritis | ICD11: FA20 | [9] |
Mirabegron |
Drug Info | Approved | Overactive bladder | ICD11: GC50 | [10] |
Opicapone |
Drug Info | Approved | Parkinsonism | ICD11: 8A00 | [11] |
Chenodeoxycholic acid |
Drug Info | Approved | Cholelithiasis | ICD11: DC11 | [12] |
Axitinib |
Drug Info | Approved | Renal cell carcinoma | ICD11: 2C90 | [13] |
Lasofoxifene |
Drug Info | Approved | Osteoporosis | ICD11: FB83 | [14] |
Naproxen |
Drug Info | Approved | Rheumatoid arthritis | ICD11: FA20 | [15] |
Repaglinide |
Drug Info | Approved | Diabetes mellitus | ICD11: 5A10 | [16] |
Belinostat |
Drug Info | Approved | Anaplastic large cell lymphoma | ICD11: 2A90 | [17], [18] |
Deferasirox |
Drug Info | Approved | Hyperphosphatemia | ICD11: 5C64 | [19] |
Desvenlafaxine |
Drug Info | Approved | Major depressive disorder | ICD11: 6A70-6A7Z | [20] |
Dolutegravir sodium |
Drug Info | Approved | Human immunodeficiency virus infection | ICD11: 1C60 | [21] |
Dronedarone hydrochloride |
Drug Info | Approved | Atrial fibrillation | ICD11: BC81 | [22] |
Etodolac |
Drug Info | Approved | Rheumatoid arthritis | ICD11: FA20 | [2] |
Exjade |
Drug Info | Approved | Hyperphosphatemia | ICD11: 5C64 | [23] |
Ibuprofen |
Drug Info | Approved | Anaesthesia | ICD11: 8E22 | [2] |
Letermovir |
Drug Info | Approved | Cytomegalovirus infection | ICD11: 1D82 | [24] |
Morphine |
Drug Info | Approved | Anaesthesia | ICD11: 8E22 | [9] |
Morphine |
Drug Info | Approved | Anaesthesia | ICD11: 8E22 | [25], [26], [27] |
Simvastatin |
Drug Info | Approved | Dyslipidaemia | ICD11: 5C81 | [28] |
Anastrozole |
Drug Info | Approved | Breast cancer | ICD11: 2C60 | [29] |
Atorvastatin calcium |
Drug Info | Approved | Dyslipidaemia | ICD11: 5C81 | [30] |
Buprenorphine hydrochloride |
Drug Info | Approved | Anaesthesia | ICD11: 8E22 | [31] |
Clofazimine |
Drug Info | Approved | Crohn disease | ICD11: DD70 | [32] |
Etravirine |
Drug Info | Approved | Human immunodeficiency virus infection | ICD11: 1C60 | [33] |
Gemfibrozil |
Drug Info | Approved | Hypertriglyceridaemia | ICD11: 5C80 | [34] |
Nalbuphine |
Drug Info | Approved | Pain | ICD11: MG30-MG3Z | [35] |
Nalmefene |
Drug Info | Approved | Opiate dependence | ICD11: 6C43 | [36] |
Avapritinib |
Drug Info | Approved | Gastrointestinal stromal tumour | ICD11: 2B5B | [37] |
Candesartan cilexetil |
Drug Info | Approved | Essential hypertension | ICD11: BA00 | [2] |
Desloratadine |
Drug Info | Approved | Allergic rhinitis | ICD11: CA08 | [38] |
Empagliflozin |
Drug Info | Approved | Diabetes mellitus | ICD11: 5A10 | [39] |
Ezetimibe |
Drug Info | Approved | Hypertriglyceridaemia | ICD11: 5C80 | [40] |
Ketotifen |
Drug Info | Approved | Conjunctivitis | ICD11: 9A60 | [41] |
Ketotifen |
Drug Info | Approved | Conjunctivitis | ICD11: 9A60 | [42] |
Lamotrigine |
Drug Info | Approved | Bipolar disorder | ICD11: 6A60 | [43] |
Losartan potassium |
Drug Info | Approved | Essential hypertension | ICD11: BA00 | [2] |
Lovastatin |
Drug Info | Approved | Hypertriglyceridaemia | ICD11: 5C80 | [28] |
Pitavastatin calcium |
Drug Info | Approved | Hypertriglyceridaemia | ICD11: 5C80 | [44] |
Troglitazone |
Drug Info | Approved | Diabetes mellitus | ICD11: 5A10 | [45] |
Ambrisentan |
Drug Info | Approved | Pulmonary hypertension | ICD11: BB01 | [46] |
Cerivastatin sodium |
Drug Info | Approved | Hypertriglyceridaemia | ICD11: 5C80 | [47] |
Eltrombopag olamine |
Drug Info | Approved | Thrombocytopenia | ICD11: 3B64 | [48] |
Elvitegravir |
Drug Info | Approved | Human immunodeficiency virus infection | ICD11: 1C60 | [49] |
Flurbiprofen sodium |
Drug Info | Approved | Rheumatoid arthritis | ICD11: FA20 | [2] |
Hesperidin |
Drug Info | Approved | Vascular purpura | ICD11: 3B60 | [50] |
Hydromorphone |
Drug Info | Approved | Anaesthesia | ICD11: 8E22 | [51] |
Loratadine |
Drug Info | Approved | Allergic rhinitis | ICD11: CA08 | [52] |
Vorinostat |
Drug Info | Approved | Cutaneous T-cell lymphoma | ICD11: 2B01 | [53] |
Baloxavir marboxil |
Drug Info | Approved | Influenza virus infection | ICD11: 1E30 | [54] |
Baloxavir marboxil |
Drug Info | Approved | Influenza virus infection | ICD11: 1E30 | [55] |
Enasidenib |
Drug Info | Approved | Acute myeloid leukaemia | ICD11: 2A60 | [56] |
Fulvestrant |
Drug Info | Approved | Breast cancer | ICD11: 2C60 | [57] |
Lorlatinib |
Drug Info | Approved | Lung cancer | ICD11: 2C25 | [58] |
Telmisartan |
Drug Info | Approved | Essential hypertension | ICD11: BA00 | [59] |
Telmisartan |
Drug Info | Approved | Essential hypertension | ICD11: BA00 | [60] |
LAROPIPRANT |
Drug Info | Phase 4 | Atherosclerosis | ICD11: BA80 | [63] |
Drugs in Phase 4 Clinical Trial | Click to Show/Hide the Full List of Drugs: 3 Drugs | ||||
Ethinylestradiol propanesulfonate |
Drug Info | Phase 4 | Prostate cancer | ICD11: 2C82 | [61], [62] |
Retigabine |
Drug Info | Phase 4 | Epilepsy | ICD11: 8A60 | [64] |
Dexibuprofen |
Drug Info | Phase 4 | Osteoarthritis | ICD11: FA00 | [2] |
Drugs in Phase 3 Clinical Trial | Click to Show/Hide the Full List of Drugs: 15 Drugs | ||||
Selumetinib |
Drug Info | Phase 3 | Neurofibromatosis | ICD11: LD2D | [65] |
ABL001 |
Drug Info | Phase 3 | Chronic myelogenous leukaemia | ICD11: 2A20 | [66] |
BMS-298585 |
Drug Info | Phase 3 | Diabetes mellitus | ICD11: 5A10 | [67] |
LAU-7b |
Drug Info | Phase 3 | Macular degeneration | ICD11: 9B78 | [68] |
Heroin |
Drug Info | Phase 3 | Opiate dependence | ICD11: 6C43 | [69] |
Losartan |
Drug Info | Phase 3 | Hypertension | ICD11: BA00-BA04 | [70] |
TAK-875 |
Drug Info | Phase 3 | Diabetes mellitus | ICD11: 5A10 | [71] |
LCQ908-NXA |
Drug Info | Phase 3 | Hypertriglyceridaemia | ICD11: 5C80 | [72] |
Fevipiprant |
Drug Info | Phase 3 | Asthma | ICD11: CA23 | [73] |
Glinsuna |
Drug Info | Phase 3 | Diabetes mellitus | ICD11: 5A10 | [2] |
Glinsuna |
Drug Info | Phase 3 | Diabetes mellitus | ICD11: 5A10 | [2], [74] |
KAD-1229 |
Drug Info | Phase 3 | Diabetes mellitus | ICD11: 5A10 | [2] |
Ag-221 |
Drug Info | Phase 3 | Acute myelogenous leukaemia | ICD11: 2A41 | [75] |
Atorvastatin |
Drug Info | Phase 3 | Hypertriglyceridaemia | ICD11: 5C80 | [30] |
CS-011 |
Drug Info | Phase 3 | Diabetes mellitus | ICD11: 5A10 | [76] |
Drugs in Phase 2 Clinical Trial | Click to Show/Hide the Full List of Drugs: 11 Drugs | ||||
PF-06463922 |
Drug Info | Phase 2 | Lung cancer | ICD11: 2C25 | [77] |
Puerarin |
Drug Info | Phase 2 | Alcohol dependence | ICD11: 6C40 | [78] |
BAICALEIN |
Drug Info | Phase 2 | Influenza virus infection | ICD11: 1E30-1E32 | [79] |
LJN452 |
Drug Info | Phase 2 | Primary biliary cholangitis | ICD11: DB96 | [80] |
S-297995 |
Drug Info | Phase 2 | Opiate dependence | ICD11: 6C43 | [81] |
PT2385 |
Drug Info | Phase 2 | Von hippel-lindau disease | ICD11: 5A75 | [82] |
AMG 232 |
Drug Info | Phase 2 | Merkel cell carcinoma | ICD11: 2C34 | [83] |
BIA 3-202 |
Drug Info | Phase 2 | Parkinsonism | ICD11: 8A00 | [84] |
BIIB074 |
Drug Info | Phase 2 | Bipolar disorder | ICD11: 6A60 | [85] |
MPC-4326 |
Drug Info | Phase 2 | Human immunodeficiency virus infection | ICD11: 1C60 | [86] |
Sitafloxacin |
Drug Info | Phase 2 | Escherichia coli infection | ICD11: 1A03 | [87] |
Drugs in Phase 1 Clinical Trial | Click to Show/Hide the Full List of Drugs: 4 Drugs | ||||
CB-3304 |
Drug Info | Phase 1/2 | Chronic lymphocytic leukaemia | ICD11: 2A82 | [88] |
BRN-0183227 |
Drug Info | Phase 1 | Acute coronary syndrome | ICD11: BA4Z | [89] |
Norbuprenorphine |
Drug Info | Phase 1 | Human immunodeficiency virus infection | ICD11: 1C60-1C62 | [90] |
OTSSP167 |
Drug Info | Phase 1 | Myelodysplastic syndrome | ICD11: 2A37 | [91] |
Discontinued/withdrawn Drugs | Click to Show/Hide the Full List of Drugs: 5 Drugs | ||||
Lexacalcitol |
Drug Info | Discontinued in Phase 2 | Solid tumour/cancer | ICD11: 2A00-2F9Z | [92], [93] |
T-5224 |
Drug Info | Discontinued in Phase 2 | Rheumatoid arthritis | ICD11: FA20 | [94] |
GV-150526 |
Drug Info | Discontinued | Cerebral stroke | ICD11: 8B11 | [2] |
ML-3000 |
Drug Info | Discontinued | Osteoarthritis | ICD11: FA00 | [95] |
ML-3000 |
Drug Info | Discontinued | Osteoarthritis | ICD11: FA00 | [2] |
Preclinical/investigative Agents | Click to Show/Hide the Full List of Drugs: 1 Drugs | ||||
Hydroxyestrone |
Drug Info | Investigative | Discovery agent | ICD: N.A. | [96] |
References | |||||
---|---|---|---|---|---|
1 | Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. | ||||
2 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. | ||||
3 | Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35. | ||||
4 | In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16. | ||||
5 | Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol Mol Pharmacol. 1993 Apr;43(4):649-54. | ||||
6 | DrugBank(Pharmacology-Metabolism):Pitavastatin | ||||
7 | Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36. | ||||
8 | In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7 Xenobiotica. 2015;45(11):990-8. doi: 10.3109/00498254.2015.1038743. | ||||
9 | Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. | ||||
10 | Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective (3)-Adrenoceptor Agonist, in Human Liver Microsomes | ||||
11 | Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping | ||||
12 | Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70. | ||||
13 | In Vitro Kinetic Characterization of Axitinib Metabolism | ||||
14 | DrugBank(Pharmacology-Metabolism):Lasofoxifene | ||||
15 | S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33. | ||||
16 | Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010 Dec;70(6):870-80. | ||||
17 | Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8(1):e54522. | ||||
18 | In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes | ||||
19 | Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554. | ||||
20 | Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine | ||||
21 | Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans | ||||
22 | DrugBank(Pharmacology-Metabolism):Dronedarone hydrochloride | ||||
23 | LABEL:Exjade | ||||
24 | LABEL:PREVYMIS- letermovir tablet, film coated PREVYMIS- letermovir injection, solution | ||||
25 | Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96. | ||||
26 | Metabolism and pharmacokinetics of morphine in neonates: A review | ||||
27 | Morphine metabolism, transport and brain disposition | ||||
28 | Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106. | ||||
29 | In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69. | ||||
30 | UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. | ||||
31 | Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010 Jan;38(1):40-5. | ||||
32 | Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro | ||||
33 | Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14. | ||||
34 | Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin Pharmacol Ther. 2018 Jul;104(1):158-168. | ||||
35 | A dual system platform for drug metabolism: Nalbuphine as a model compound | ||||
36 | Ema.europa:Nalmefene | ||||
37 | FDA label:Avapritinib | ||||
38 | A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement Drug Metab Dispos. 2015 Apr;43(4):523-33. doi: 10.1124/dmd.114.062620. | ||||
39 | Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8. | ||||
40 | Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8. | ||||
41 | N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group Drug Metab Dispos. 1998 Sep;26(9):830-7. | ||||
42 | Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab Dispos. 2013 Jul;41(7):1389-97. | ||||
43 | Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63. | ||||
44 | Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168. | ||||
45 | Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9. | ||||
46 | Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805. | ||||
47 | Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8. | ||||
48 | Eltrombopag for use in children with immune thrombocytopenia Blood Adv. 2018 Feb 27;2(4):454-461. doi: 10.1182/bloodadvances.2017010660. | ||||
49 | In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4 | ||||
50 | U. S. FDA Label -Hesperidin | ||||
51 | Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14. | ||||
52 | Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62. | ||||
53 | Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85. | ||||
54 | FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration. | ||||
55 | Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects | ||||
56 | FDA:Enasidenib | ||||
57 | Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol. 2006 Mar;69(3):908-20. | ||||
58 | FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration. | ||||
59 | Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012 Apr;40(4):825-35. | ||||
60 | In vitro glucuronidation of the angiotensin II receptor antagonist telmisartan in the cat: a comparison with other species | ||||
61 | Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk Eur J Intern Med. 2017 Jul;42:54-60. doi: 10.1016/j.ejim.2017.05.019. | ||||
62 | Metabolism of 17 alpha-ethinylestradiol by human liver microsomes in vitro: aromatic hydroxylation and irreversible protein binding of metabolites J Clin Endocrinol Metab. 1974 Dec;39(6):1072-80. doi: 10.1210/jcem-39-6-1072. | ||||
63 | Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans | ||||
64 | Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12. | ||||
65 | Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens | ||||
66 | Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants | ||||
67 | Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80. | ||||
68 | Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99. | ||||
69 | PharmGKB:Heroin | ||||
70 | The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72. | ||||
71 | Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445. | ||||
72 | Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089. | ||||
73 | Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator. Drug Metab Dispos. 2021 May;49(5):389-394. doi: 10.1124/dmd.120.000273. | ||||
74 | Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51. | ||||
75 | DrugBank(Pharmacology-Metabolism):Ag-221 | ||||
76 | In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9. | ||||
77 | The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants | ||||
78 | UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes | ||||
79 | Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein | ||||
80 | Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism | ||||
81 | Naldemedine: First Global Approval | ||||
82 | Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2 Inhibitor PT2385 In Vivo and In Vitro | ||||
83 | Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation | ||||
84 | Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation | ||||
85 | Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers | ||||
86 | Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13. | ||||
87 | Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes | ||||
88 | Metabolic map and bioactivation of the anti-tumour drug noscapine | ||||
89 | Stratification of Volunteers According to Flavanone Metabolite Excretion and Phase II Metabolism Profile after Single Doses of 'Pera' Orange and 'Moro' Blood Orange Juices | ||||
90 | Chemical and enzyme-assisted syntheses of norbuprenorphine-3--D-glucuronide | ||||
91 | Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10 | ||||
92 | Metabolism of 1,8-cineole by human cytochrome P450 enzymes: identification of a new hydroxylated metabolite. Biochim Biophys Acta. 2005 Apr 15;1722(3):304-11. doi: 10.1016/j.bbagen.2004.12.019. | ||||
93 | Performance comparison between multienzymes loaded single and dual electrodes for the simultaneous electrochemical detection of adenosine and metabolites in cancerous cells. Biosens Bioelectron. 2018 Jun 30;109:263-271. doi: 10.1016/j.bios.2018.03.031. | ||||
94 | Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms | ||||
95 | In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase. Drug Metab Dispos. 2008 May;36(5):894-903. | ||||
96 | Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99. | ||||
97 | Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009 Jun;49(6):719-24. | ||||
98 | Hepatic metabolism and disposition of baicalein via the coupling of conjugation enzymes and transporters-in vitro and in vivo evidences | ||||
99 | Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49. | ||||
100 | Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection Drug Metab Dispos. 2006 Mar;34(3):427-39. doi: 10.1124/dmd.105.007617. | ||||
101 | In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95. | ||||
102 | Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome. Drug Alcohol Depend. 2023 Jun 21;249:110832. doi: 10.1016/j.drugalcdep.2023.110832. | ||||
103 | Determination of buprenorphine, norbuprenorphine, naloxone, and their glucuronides in urine by liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2021 Sep;13(9):1658-1667. doi: 10.1002/dta.3104. | ||||
104 | Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70. | ||||
105 | Human metabolism of cyproheptadine | ||||
106 | Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state Drug Metab Dispos. 2010 May;38(5):808-16. doi: 10.1124/dmd.109.030833. | ||||
107 | DrugBank(Pharmacology-Metabolism)Diclofenac sodium | ||||
108 | Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018 Feb 27;2(4):454-461. | ||||
109 | Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease | ||||
110 | Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects Drug Metab Dispos. 2013 Feb;41(2):445-56. doi: 10.1124/dmd.112.049551. | ||||
111 | Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635. | ||||
112 | Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561-74. | ||||
113 | Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94. | ||||
114 | Bioequivalence Study of Ezetimibe Tablets After a Single Oral Dose of 10?mg in Healthy Japanese Subjects Under Fasting Conditions. Clin Pharmacol Drug Dev. 2023 Apr 6. doi: 10.1002/cpdd.1245. | ||||
115 | Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol?:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects. BMC Pharmacol Toxicol. 2023 Feb 3;24(1):7. doi: 10.1186/s40360-023-00649-y. | ||||
116 | Investigation of the discriminatory ability of analytes for the bioequivalence assessment of ezetimibe: Parent drug, metabolite, total form, and combination of parent drug and total form. Eur J Pharm Sci. 2022 Jul 1;174:106192. doi: 10.1016/j.ejps.2022.106192. | ||||
117 | Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes | ||||
118 | DrugBank(Pharmacology-Metabolism):Flurbiprofen | ||||
119 | Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557. | ||||
120 | The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4. | ||||
121 | Hydromorphone | ||||
122 | Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011 Sep;17 Suppl 11:S276-87. | ||||
123 | Biotransformation of irbesartan in man Drug Metab Dispos. 1998 May;26(5):408-17. | ||||
124 | Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients | ||||
125 | Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):1009-18. doi: 10.1517/17425255.2.6.1009. | ||||
126 | Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS/MS in epileptic patients. J Pharm Biomed Anal. 2022 Oct 25;220:115017. doi: 10.1016/j.jpba.2022.115017. | ||||
127 | UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers. Xenobiotica. 2021 Oct;51(10):1146-1154. doi: 10.1080/00498254.2021.1972492. | ||||
128 | Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35. | ||||
129 | #N/A | ||||
130 | #N/A | ||||
131 | Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. | ||||
132 | The potent inhibition of human cytosolic sulfotransferase 1A1 by 17-ethinylestradiol is due to interactions with isoleucine 89 on loop 1 Horm Mol Biol Clin Investig. 2014 Dec;20(3):81-90. doi: 10.1515/hmbci-2014-0028. | ||||
133 | Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences | ||||
134 | Isolation of a novel morphinan 3-O-diglucuronide metabolite from dog urine | ||||
135 | Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1 Xenobiotica. 2016;46(1):1-13. doi: 10.3109/00498254.2015.1047812. | ||||
136 | Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor | ||||
137 | Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003 Jan;33(1):27-41. | ||||
138 | Retigabine: the newer potential antiepileptic drug | ||||
139 | N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006 Jun;55(6):711-21. | ||||
140 | Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects | ||||
141 | Simvastatin Tablet, Film-Coated |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.